These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 33137515

  • 21. Co-spray dried carbohydrate microparticles: crystallisation delay/inhibition and improved aerosolization characteristics through the incorporation of hydroxypropyl-β-cyclodextrin with amorphous raffinose or trehalose.
    Amaro MI, Tajber L, Corrigan OI, Healy AM.
    Pharm Res; 2015 Jan; 32(1):180-95. PubMed ID: 25074469
    [Abstract] [Full Text] [Related]

  • 22. Design and comprehensive characterization of dry powder inhalation aerosols of simvastatin DPPC/DPPG lung surfactant-mimic nanoparticles/microparticles for pulmonary nanomedicine.
    Encinas-Basurto D, Acosta MF, Eedara BB, Fineman JR, Black SM, Mansour HM.
    RSC Adv; 2024 Sep 12; 14(40):29413-29427. PubMed ID: 39285876
    [Abstract] [Full Text] [Related]

  • 23. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J, Chan HK, Gengenbach T, Denman JA.
    Eur J Pharm Biopharm; 2017 Oct 12; 119():224-234. PubMed ID: 28655664
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols.
    Lee HJ, Kang JH, Lee HG, Kim DW, Rhee YS, Kim JY, Park ES, Park CW.
    Drug Des Devel Ther; 2016 Oct 12; 10():4017-4030. PubMed ID: 28008226
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N, Ahn P, Park H, Bhujbal S, Zemlyanov D, Cavallaro A, Mangal S, Li J, Zhou QT.
    Mol Pharm; 2018 Sep 04; 15(9):4004-4020. PubMed ID: 30028947
    [Abstract] [Full Text] [Related]

  • 29. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection.
    Arora S, Haghi M, Loo CY, Traini D, Young PM, Jain S.
    Mol Pharm; 2015 Jun 01; 12(6):2001-9. PubMed ID: 25923171
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L, Sun S, Parumasivam T, Denman JA, Gengenbach T, Tang P, Mao S, Chan HK.
    Eur J Pharm Biopharm; 2016 May 01; 102():132-41. PubMed ID: 26970252
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part I: In Vitro Testing and Characterization.
    Momin MAM, Farkas D, Hindle M, Hall F, DiBlasi RM, Longest W.
    Pharm Res; 2024 Aug 01; 41(8):1703-1723. PubMed ID: 39112775
    [Abstract] [Full Text] [Related]

  • 35. Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles.
    Xu Y, Harinck L, Lokras AG, Gerde P, Selg E, Sjöberg CO, Franzyk H, Thakur A, Foged C.
    Int J Pharm; 2022 Jun 10; 621():121758. PubMed ID: 35483619
    [Abstract] [Full Text] [Related]

  • 36. Formulating Inhalable Dry Powders Using Two-Fluid and Three-Fluid Nozzle Spray Drying.
    Leng D, Thanki K, Foged C, Yang M.
    Pharm Res; 2018 Nov 01; 35(12):247. PubMed ID: 30386927
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
    Babenko M, Alany RG, Calabrese G, Kaialy W, ElShaer A.
    Int J Pharm; 2022 Apr 05; 617():121601. PubMed ID: 35181460
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Assessment of Dry Powder Inhaler Carrier Targeted Design: A Comparative Case Study of Diverse Anomeric Compositions and Physical Properties of Lactose.
    Pinto JT, Zellnitz S, Guidi T, Roblegg E, Paudel A.
    Mol Pharm; 2018 Jul 02; 15(7):2827-2839. PubMed ID: 29856921
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.